Novartis AG (NVS) is currently priced at $145.08, marking an increase of 89 cents (0.617%) from the previous close of $144.19. Trading volume is notable at $1.16 million, representing a 51.63% deviation from the average.
On Monday, April 27th, Novartis reported earnings with a consensus estimate EPS of 2.1, reflecting a positive outlook.
Novartis boasts a forward dividend yield of 8.5%, with a dividend per share MRQ of $3.08, showcasing a 5.7397 cents increase year-over-year.
The company generated a free cash flow of $1.64 billion, with significant cash inflows and outflows, resulting in a net change in cash of $1.88 billion.
Novartis reported a revenue of $13.33 billion, with a gross profit of $9.79 billion. Operating income stood at $3.52 billion, leading to a net income of $2.41 billion and an EPS of $1.26.
Key ratios indicate Novartis's solid performance, with notable figures such as a gross profit margin of 73.44%, return on equity of 5.27%, and a price-to-earnings ratio of 27.22.
Novartis showcases a strong financial position with total assets of $115.57 billion and total liabilities of $69 billion, reflecting a robust balance sheet structure.
This comprehensive overview highlights Novartis's financial strength and positive market performance, positioning the company well in the current economic landscape.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.